Comprehensive Genomic Profiling for Solid Tumors and Hematologic Malignancies
The IVDNGS™ Extended All Cancer Panel is a cutting-edge, Next-Generation Sequencing (NGS)-based assay developed for in vitro diagnostic use. This extensive panel is designed to detect a wide range of genetic mutations, fusions, insertions/deletions (indels), and copy number variations (CNVs) across hundreds of cancer-associated genes. It is a powerful tool for the diagnosis, prognosis, treatment selection, and monitoring of both solid tumors and hematological cancers.
Built for high clinical utility, this panel enables precision oncology by delivering comprehensive genomic insights that inform targeted therapies, immunotherapies, and personalized treatment decisions.
Covers 500+ genes associated with various cancer types
Detects SNVs, indels, CNVs, gene fusions, and splice variants
Includes genes linked to targeted therapies, tumor suppressors, and biomarkers
Compatible with FFPE, fresh-frozen tissue, and liquid biopsy (cfDNA)
Integrated bioinformatics pipeline with clinical-grade variant annotation
Compliant with IVD standards and ISO 13485
Solid tumors: Lung, breast, colon, pancreas, liver, prostate, ovarian, etc.
Hematologic malignancies: Leukemia, lymphoma, myeloma
Tumor mutation burden (TMB) & microsatellite instability (MSI) analysis
Companion diagnostics for FDA-approved targeted drugs
Resistance mutation detection in relapsed/refractory cases
| Parameter | Details |
|---|---|
| Sample Type | FFPE tissue, fresh tissue, cfDNA (plasma) |
| DNA Input Requirement | 50–200 ng |
| Turnaround Time | 7–10 working days |
| Platform Compatibility | Illumina NGS systems |
| Report Output | Clinically relevant mutations, TMB, MSI, gene fusions |
Copyright © 2025 https://probgenbiotech.com/ All Rights Reserved.